BRPI0514470A - 5-[3-(4-benziloxifeniltio)-fur-2-il]-imidazolin-2, 4-diona e análogos como inibidores de elastase macrofágica - Google Patents

5-[3-(4-benziloxifeniltio)-fur-2-il]-imidazolin-2, 4-diona e análogos como inibidores de elastase macrofágica

Info

Publication number
BRPI0514470A
BRPI0514470A BRPI0514470-1A BRPI0514470A BRPI0514470A BR PI0514470 A BRPI0514470 A BR PI0514470A BR PI0514470 A BRPI0514470 A BR PI0514470A BR PI0514470 A BRPI0514470 A BR PI0514470A
Authority
BR
Brazil
Prior art keywords
benzyloxyphenylthio
fur
dione
imidazolin
macrophage elastase
Prior art date
Application number
BRPI0514470-1A
Other languages
English (en)
Inventor
Fude Yang
Original Assignee
Quest Pharmaceutical Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmaceutical Services filed Critical Quest Pharmaceutical Services
Publication of BRPI0514470A publication Critical patent/BRPI0514470A/pt
Publication of BRPI0514470B1 publication Critical patent/BRPI0514470B1/pt
Publication of BRPI0514470B8 publication Critical patent/BRPI0514470B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

5- ¢3- (4-BENZILOXIFENILTIO) -FUR-2-IL! -IMIDAZOLIN-2,4-DIONA E ANáLOGOS COMO INIBIDORES DE ELASTASE MACROFáGICA 5-{ ¢3- (4-benziloxifeniltio) -fur-2-il! }-imidazolin-2,4-diona e análogos úteis como inibidores de elastase macrofágica são revelados.
BRPI0514470A 2004-08-19 2005-08-17 composto 5-[3-(4-benziloxifeniltio)-fur-2-il]-imidazolin-2,4-diona e composição farmacêutica BRPI0514470B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60273604P 2004-08-19 2004-08-19
US60/602.736 2004-08-19
PCT/US2005/029259 WO2006023562A2 (en) 2004-08-19 2005-08-17 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase

Publications (3)

Publication Number Publication Date
BRPI0514470A true BRPI0514470A (pt) 2008-06-10
BRPI0514470B1 BRPI0514470B1 (pt) 2021-01-05
BRPI0514470B8 BRPI0514470B8 (pt) 2021-07-20

Family

ID=35968136

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514470A BRPI0514470B8 (pt) 2004-08-19 2005-08-17 composto 5-[3-(4-benziloxifeniltio)-fur-2-il]-imidazolin-2,4-diona e composição farmacêutica

Country Status (16)

Country Link
US (1) US7179831B2 (pt)
EP (1) EP1789036B1 (pt)
JP (1) JP5042833B2 (pt)
KR (1) KR101197325B1 (pt)
CN (1) CN101014338B (pt)
AT (1) ATE508744T1 (pt)
AU (1) AU2005277432B2 (pt)
BR (1) BRPI0514470B8 (pt)
CA (1) CA2577430C (pt)
DK (1) DK1789036T3 (pt)
ES (1) ES2364068T3 (pt)
MX (1) MX2007001940A (pt)
NZ (1) NZ553258A (pt)
RU (1) RU2391339C2 (pt)
SI (1) SI1789036T1 (pt)
WO (1) WO2006023562A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051260A1 (en) * 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CA3034032C (en) * 2016-08-19 2021-05-25 Foresee Pharmaceuticals Co., Ltd. Compositions comprising inhibitors of macrophage elastase and cyclodextrin
ES2865854T3 (es) * 2016-09-23 2021-10-18 Kaken Pharma Co Ltd Método para producir (r)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]imidazolidin-2,4-diona y un producto intermedio para producir la misma
EP4335499A3 (en) * 2018-05-15 2024-05-15 Foresee Pharmaceuticals USA, Inc. Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
US11673884B2 (en) * 2019-11-14 2023-06-13 Foresee Pharmaceuticals Co., Inc. Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
EP4351566A4 (en) * 2021-06-08 2025-04-23 Foresee Pharmaceuticals USA, Inc. SAFE ADMINISTRATION OF MMP-12 INHIBITOR
RU2766551C1 (ru) * 2021-07-19 2022-03-15 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352976B1 (en) * 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
WO2000040577A1 (en) 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
RU2150469C1 (ru) * 1999-06-01 2000-06-10 Уфимский государственный нефтяной технический университет Способ получения 2-(фурил-2)-1,3-имидазолидинов
US6897237B2 (en) 2000-04-28 2005-05-24 Shionogi & Co. Ltd. MMP-12 inhibitors
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
AU2003282920A1 (en) * 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)

Also Published As

Publication number Publication date
CA2577430C (en) 2010-12-07
BRPI0514470B8 (pt) 2021-07-20
JP2008510701A (ja) 2008-04-10
DK1789036T3 (da) 2011-06-27
RU2391339C2 (ru) 2010-06-10
ES2364068T3 (es) 2011-08-24
US20060041000A1 (en) 2006-02-23
MX2007001940A (es) 2007-07-24
JP5042833B2 (ja) 2012-10-03
WO2006023562A3 (en) 2006-04-20
ATE508744T1 (de) 2011-05-15
CN101014338A (zh) 2007-08-08
SI1789036T1 (sl) 2011-09-30
EP1789036A4 (en) 2008-08-27
EP1789036A2 (en) 2007-05-30
HK1107774A1 (en) 2008-04-18
US7179831B2 (en) 2007-02-20
NZ553258A (en) 2011-02-25
KR20070045330A (ko) 2007-05-02
CN101014338B (zh) 2010-06-16
KR101197325B1 (ko) 2012-11-05
AU2005277432A1 (en) 2006-03-02
EP1789036B1 (en) 2011-05-11
BRPI0514470B1 (pt) 2021-01-05
AU2005277432B2 (en) 2011-11-24
WO2006023562A2 (en) 2006-03-02
CA2577430A1 (en) 2006-03-02
RU2007105822A (ru) 2008-09-27
WO2006023562B1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
PT2275102E (pt) Derivados de benzimidazole alquilado n3 como inibidores de mek
EP4125244C0 (en) HASH BASED MULTIHOSTING
NO20053161D0 (no) Mikrobedrepende sammensetning.
EA200701918A1 (ru) Белок липокалин
NO20082298L (no) Kaliumkanalinhibitorer
DE602005021959D1 (de) Substituierte diazaspiroä4.5üdecanderivate und der
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
DK2468732T3 (da) 1H-Quinazolin-2,4-dioner
ATE527362T1 (de) Verbesserte expression zeigendemodifizierte xylanasen
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
EP1723247A4 (en) RECOMBINANT PERFORIN, ITS EXPRESSION AND USES
DE602005018653D1 (de) Aktive auswahl der bestätigungsquelle
FI20041419A0 (fi) Soodakattilan keon hallinta
MX2007001940A (es) 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolidin-2,4-diona y analogos como inhibidores de macrofago elastasa.
BRPI0719836A2 (pt) Clonagem, expressão e uso de fosfolipases ácidas.
EP1910272A4 (en) Renin Inhibitors
BRPI0816810A2 (pt) utilização de pelo menos um composto, e, composto.
NO20081069L (no) Dynamisk, anvendelsesutvidende teknologi
ES1056879Y (es) Plomada laser.
ES1059759Y (es) Multibolsa de basura.
FR2867349B1 (fr) Epandeur de fumier.
ES1058173Y (es) Viga de poliuretano chapada.
ES1057865Y (es) Desatascador de desagues.
ES1060365Y (es) Frigorifico partido.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: FORESEE PHARMACEUTICALS, CO., LTD. (CN)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2609 DE 05/01/2021 QUANTO AO DESENHO E O RESUMO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2683 DE 07-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.